echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Astellas-targeted Claudin18.2 antibody approved for clinical treatment of pancreatic cancer in China

    Astellas-targeted Claudin18.2 antibody approved for clinical treatment of pancreatic cancer in China

    • Last Update: 2022-03-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 10, the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of the People's Republic of China announced that the zolbetuximab for injection declared by Astellas has obtained an implied license for a clinical trial in China, and the indication is metastatic pancreas.


    Screenshot source: CDE official website

    Claudins proteins are tight junction molecules


    Although Claudin 18.


    In China, zolbetuximab was first approved for clinical use in 2018 for the indication of locally advanced unresectable or metastatic, Claudin18.


    The ClinicalTrials.


    It is hoped that the follow-up clinical study of zolbetuximab will proceed smoothly and bring new treatment options to patients as soon as possible


    References:

    [1] The official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.